The adenosine 2a receptor and TIM3 directly inhibit killing of tumor cells by cytotoxic T lymphocytes through interference with cytoskeletal polarization
G. L. Edmunds, C. W. L. Wong, R. Ambler, E. Milodowski, H. Alamir, S. J. Cross, G. Galea, C. Wuelfing, D. J. Morgan
Abstract
Tumors generate an immune-suppressive environment that prevents effective killing of tumor cells by CD8+ cytotoxic T cells (CTL). It remains largely unclear upon which cell type and at which stage of the anti-tumor response mediators of suppression act. We have combined an in vivo tumor model with a matching in vitro reconstruction of the tumor microenvironment based on tumor spheroids to identify suppressors of anti-tumor immunity that directly act on interaction between CTL and tumor cells and to determine mechanisms of action. An adenosine 2a receptor antagonist, as enhanced by blockade of TIM3, slowed tumor growth in vivo. Engagement of the adenosine 2a receptor and TIM3 reduced tumor cell killing in spheroids, impaired CTL cytoskeletal polarization ex vivo and in vitro and inhibited CTL infiltration into tumors and spheroids. With this focus on CTL killing, blocking A2aR and TIM3 complements therapies that enhance T cell priming, e.g. anti-PD1 and anti-CTLA-4.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A2AR-mediated inhibition of B cell maturation: a novel mechanism of immune suppression in cancer
Paola Tieppo, Hussein Shehade, … Maura Maria Rossetti·bioRxiv·Aug 13, 2025
- TIM3 is a context-dependent co-regulator of cytotoxic T cell function
H. Alamir, C. W. C. Wong, … C. Wuelfing·bioRxiv·Aug 3, 2023
- Interaction with tumor cell spheroids induces suppression in primary human cytotoxic T cells
Amal Alsubaiti, Hanin Alamir, … Christoph Wülfing·Immunotherapy AdvancesPeer-reviewed·Dec 30, 2024
- Targeting CD73-A2aR-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance
Shruti Bansal, Luis Aparicio, … Catherine S. Spina·bioRxiv·May 29, 2026
- SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies
Quoc Thang Bui, Raghavendra Basavaraja, … Serge Yu. Fuchs·bioRxiv·Apr 1, 2026
- A2A Receptor contributes to tumor progression in P2X7 null mice
E. De Marchi, A. Pegoraro, … E. Adinolfi·bioRxiv·Feb 28, 2022